Navigation Links
Organovo Named 2015 Technology Pioneer by World Economic Forum

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, announced today that it has been recognized as a 2015 Technology Pioneer by the World Economic Forum (WEF).  Organovo is one of 24 companies honored for the ability to harness creativity to design and create transformative solutions.

"We are honored to be named a Technology Pioneer by the World Economic Forum for the innovation and power of Organovo's 3D bioprinting technology," said Keith Murphy, president and CEO of Organovo.  "We see this as a recognition of our team's hard work and dedication to our mission to improve health and medicine on a global scale."  

Organovo's leading, commercial 3D bioprinting technology enables the creation of functional human tissues that more accurately reproduce native tissues. The company develops a range of tissue and disease models for medical research, drug testing and therapeutic applications.

"The impact of technology continues to accelerate in all domains of society," said Fulvia Montresor, director, head of Technology Pioneers at the World Economic Forum. "To better understand the breadth and depth of this impact, CEOs and other leaders have come to depend on their interactions with the Technology Pioneers and their diverse and innovative solutions."

Each year since 2000, the World Economic Forum chooses its Technology Pioneers from hundreds of applicants that are vetted by a distinguished selection committee of technology and innovation experts.

Organovo and the 2015 Technology Pioneers will be honored at a ceremony on September 11 at the eighth Annual Meeting of the New Champions. The Meeting is the foremost gathering in Asia on science, technology, innovation and entrepreneurship.

More information about the World Economic Forum's Technology Pioneers programme can be found at

About Organovo Holdings, Inc. 

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company plans to market the first product of a planned portfolio offering, 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing prior to the end of 2014, and remains on track to bring this breakthrough technology to customers.  In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 as well as our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
2. Organovo Holdings, Inc. to Webcast, Live, at December 5th
3. Organovo Provides Guidance on Upcoming Retail Investor Conference
4. Organovo Cautions Investors in Regards to "Short and Distort" Articles
5. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
6. Organovo Holdings, Inc. Prices $40.5 Million Public Offering of Common Stock
7. Organovo and Methuselah Foundation Announce Funding of Bioprinting Research at Research Institutions
8. Organovo Reports Fiscal 2013 Financial Results
9. Organovo Holdings, Inc. Announces Change of Fiscal Year
10. Organovo Reports 2012 Financial Results
11. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):